#USA #Scinai Immunotherapeutics #CDMO Services #NanoAbs #Miami, San Francisco

Scinai Immunotherapeutics Prepares for Major US Conferences

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a leading player in the biopharmaceutical industry, is gearing up to make a significant impact at two major conferences in the United States. The company's CEO, Mr. Amir Reichman, and the Chairman of the Board, Mr. Mark Germain, are scheduled to attend the IATI Mini Mixiii Conference in Miami, Florida on January 9, 2025, and the JP Morgan HealthCare Conference in San Francisco from January 13-15, 2025. Additionally, on January 14, they will participate in the SIC Biotech Symposium also held in San Francisco.

Focusing on Collaborations and Growth

During these key industry events, Mr. Reichman and Mr. Germain aim to connect with a variety of stakeholders. They will engage in meetings with both institutional and private investors who are keen to learn about Scinai's value proposition and growth potential in the biotech sector. These discussions will be vital for attracting investment and expanding the company's reach in the evolving landscape of immunotherapy.

In addition to investors, Scinai is targeting potential pharmaceutical partners, particularly those with interest in co-developing or in-licensing Scinai's innovative nano-sized VHH antibodies, known as NanoAbs. These products are designed to address unmet medical needs in inflammation and immunology, reflecting the company’s commitment to advancing healthcare solutions.

Scinai is also looking to showcase its Contract Development and Manufacturing Organization (CDMO) services, which form a critical component of the company’s operations. Their comprehensive capabilities include drug development, analytical methods, clinical trials, and cGMP manufacturing services tailored for early-stage biotech projects. The availability of these services could be a significant draw for new clients seeking reliable partners in biologics development.

Scheduling Opportunities for Interested Parties

Scinai encourages interested parties to arrange meetings through various channels such as the Mini Mixiii conference partnering platform and CSSi partnering system, or by reaching out directly via email at contact@scinai.com. This proactive approach highlights the company’s eagerness to pave pathways for future collaborations and success.

Highlighting Recent Achievements

Recently, Scinai has taken the opportunity to release a year-end video capturing the key accomplishments and milestones the company achieved throughout 2024. This highlights not only their growth trajectory but also their innovation-driven agenda as they prepare for these significant public appearances. For those interested in learning more about their recent successes, the year-end video can be viewed here.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics operates with two main business units: one focused on pioneering biological therapeutic products specifically targeting inflammation and immunology and a second unit offering specialized CDMO services. Their unique pipeline includes de-risked nanoAbs that are designed to tackle critical health issues, underlining their strategic vision to improve patient outcomes through advanced biotherapeutics.

For more information or inquiries about partnership opportunities, stakeholders can visit Scinai's official website at www.scinai.com.

As Scinai Immunotherapeutics prepares for these conferences, the biotech community eagerly anticipates the innovations and collaborations that may emerge from these pivotal interactions. The company’s positioning at such prominent events signifies its readiness to thrive in a competitive landscape, dedicated to addressing the essential needs within the healthcare sector.